- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02845583
Nursing Activities for High Complexity Oncologic Care Patients
Quantifying and Measuring the Economic Impact of Nursing Activities During the Hospital Stay of High Complexity Oncologic Care Patients
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Study design
The methodological approach used to achieve the objective of this research is quantitative. A mixed study design is being adopted:
- Retrospective study to determine the nature and volume of activity provided at nursing classes of patients whose admission is attributed to a specific DRG
- Longitudinal prospective study to determine the variability of costs of nurses with regard to DRG refund, comparatively to distribution of patients for every single section (high, medium, low complexity).
Study population The sample has been chosen considering the prevalence of hospitalizations per year in medical oncology U.O.C. related to certain DRG and characterized by greater complexity of care, so as to provide a useful information base for study. For the retrospective study the survey will be conducted on a sample of 150 patients. Patients will be enrolled at high, medium and low complexity of care, hospitalized for chemotherapy and for biliary obstructive urinary tract and in the first half of 2016. It is estimated that the sample represents 30% of the total number of admissions made in 2016. A prospective longitudinal study will take into consideration a sample of 150 patients with the same characteristics considered for enrollment in the retrospective study.
The study will include patients who under go: CHT with a duration of hospital stay of 2-3 days (microcitomi and NHL), CHT with a length of hospital stay of 4-5 days (sarcomas), CHT with a length of hospital stay > 5 days or at high doses (testicle cancer, Ewing's sarcoma and bone sarcoma) and patients with higher complexity care.
Patients of 18 years of age or less will be excluded, as well as patients that were transferred to other units while inpatient, patients transferred in U.O.C. of Oncology after major surgery procedures in other departments, and admissions that are outliers.
The duration for the monitoring phase on the allocation and the distribution of patients among the different sections of hospital care intensity (Intensità di cure, IC) and care complexity (Complessità Assistenziale, CA), based on the results obtained by the Triage of corridor (TriCO), is estimated for 3 months up to a maximum of six months starting from March 2016. For the collection of data relating to the amount and types of activities provided in the first half of 2016 is estimated to have a maximum of 30 days and others 30 days for the detection the relative DRG reimbursed for hospitalizations considered.
Survey instruments
- Professional Assessment Instrument (PAI). It is a tool that documents nursing processes implemented in a computerized way using nursing language according to the North American Nursing Diagnosis Association International (NANDA-I).
- Hospital discharge card (Scheda di dimissione ospedaliera, SDO). It is a tool that contains information about each patient discharged, that are necessary for the attribution to DRG and for finding the rate payable for each episode of hospitalization
- Scheda di mobilità interna dei pazienti. It is a card that contains data of Tri-CO at the entrance of the patient and any variations of that index during hospitalization.
Interventions The study will be presented to the manager and coordinator of the U.O.C. Medical Oncology through a moment of training/information.
In order to collect data on the variation of Tri-CO during hospitalization, and consequently the different allocation to U.O.C. of Oncology of patients in sections of low, medium and high complexity of care, a point of contact (nurse) will be identified who will deal with the collection and retention of such information in the manner set out in the research protocol.
Outcome measures
The primary outcome expected by the survey is the quantification of the volume of nursing activities provided to patients and its cost. In addition, we expect to realize economic indicators which make it possible to ascertain:
- Cost weight of the nursing staff on the DRG rate reimbursed in relation to the complexity care of the patient;
- Cost weight of the nursing staff on the reimbursement for hospitalization in connection with the DRG of patient discharge.
- Gap between theoretical and actual cost of nurses in relation to the care delivered for a specific patient; Knowledge of actual costs for each distinct and specific episode of hospitalization would enhance its "uniqueness". An economic analysis of labor nursing costs for individual patient could provide input for the determination of the costs of all the professionals of the Foundation, contributing to the improvement of corporate strategic management for resource allocation.
Statistical analysis Statistical analyses will be performed using methods of descriptive statistics and inferential statistics appropriate to the sample size and study variables. Prospective longitudinal study will be used to determine the frequency distribution and the variance on the stay of the patients in each individual section of hospital in-patient treatment which is attributed to a specific DRG. Then a factorial analysis and regression techniques will be used to measure the type of bond that exists between the dependent variable Y (nursing) and independent variables X1, X2, X3 ... (DRG, age, days of hospitalization, complications, etc). Then the analysis will continue by studying which variables will affect the distribution of patients for IC and CA level and how it can change this assignment during a single in-patient episode, creating a variability in costs of services paid.
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studie Locaties
-
-
-
Roma, Italië, 00168
- Werving
- Universita Cattolica del Sacro Cuore
-
Contact:
- Amelia Palinuro, PhD Student
- Telefoonnummer: +393468599660
- E-mail: amelia.stop@hotmail.it
-
Contact:
- Maurizio Zega, PhD
- Telefoonnummer: +390630154796
- E-mail: maurizio.zega@policlinicogemelli.it
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- CHT with a duration of hospital stay of 2-3 days (microcitomi and NHL),
- CHT with a length of hospital stay of 4-5 days (sarcomas),
- CHT with a length of hospital stay > 5 days (in case of high doses: testicle cancer, Ewing's sarcoma and bone sarcoma)
- Oncologic patients with higher complexity care.
Exclusion Criteria:
- Patients of 18 years of age or less
- Patients transferred to other units while inpatient
- Patients transferred in U.O.C. of Oncology after major surgery procedures in other departments
- Outlier admissions
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
---|
Retrospective cohort
150 oncologic patients belonging to major complexity DRGs
|
Perspective cohort
150 oncologic patients belonging to major complexity DRGs
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Volume of Nursing Activity
Tijdsspanne: Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Count of nusing activities performed to patients in different complexity groups
|
Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Cost weight of the nursing staff on the DRG rate reimbursed in relation to the complexity care (Complessità Assistenziale, CA) of the patient.
Tijdsspanne: Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Cost weight of the nursing staff on the DRG rate reimbursed in relation to the complexity care of the patient
|
Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Cost weight of the nursing staff on the reimbursement for hospitalization in connection with the DRG of patient discharge
Tijdsspanne: Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Cost weight of the nursing staff on the reimbursement for hospitalization in connection with the DRG of patient discharge.
|
Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Mean difference between theoretical and actual cost of nurses in relation to the care delivered for a specific patient.
Tijdsspanne: Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Difference between theoretical and actual cost of nurses in relation to the care delivered for a specific patient.
The nursing time cost expressed in minutes results from the standard cost for each nursing hour worked by a nurse.
The time in minutes of the performance is detected by the time indicated on standard nursing protocols considered for the study.
The time in minutes of a benefit provided to specific types of patients considered comes from the average execution time of nursing care.
|
Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- FAG14
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Kanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Nog niet aan het wervenAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten